Aerobic fitness, mitochondrial dysfunction, and fatty liver disease

描述(申请人提供)：非酒精性脂肪性肝病(NAFLD)可进展为包括非酒精性脂肪性肝炎、肝硬变和肝细胞癌。NAFLD还与肝脏胰岛素抵抗的发展有关，后者是2型糖尿病发展的主要参与者。最近的临床数据表明，有氧适应能力低下的患者发生NAFLD的易感性增加。此外，我们的研究小组和其他研究人员的证据表明，肝脏线粒体功能障碍是NAFLD和肝脏胰岛素抵抗发生的主要特征。我们的初步证据表明，肝脏线粒体功能障碍(低线粒体含量和脂肪酸氧化减少(FAOX))是有氧适应能力低下与NAFLD和肝脏胰岛素抵抗易感性增加之间的联系。然而，这些因素与线粒体功能障碍导致非酒精性脂肪肝的潜在机制(S)之间的联系仍不清楚。为了揭开这些联系，我们将研究两个新品系的大鼠[高或低能力跑步者(HCR/LCR)]，由于双向发散的选择性繁殖，它们的内在有氧适应水平不同30%。与高Fit-Hcr大鼠相比，低Fit-LCR大鼠在年轻时表现出线粒体含量、脂肪酸氧化(FAOX)和NAFLD减少，肝脏损伤明显加重。因此，高Fit-Hcr和低Fit-LCR菌株为研究有氧健身对肝脏代谢的作用提供了一个新的实验平台。这一建议的中心假设是，由于线粒体功能障碍，低有氧适应能力会增加NAFLD和肝脏胰岛素抵抗的风险。其具体目的如下：目的1)测试低Fit-LCR大鼠是否增加了对脂质诱导的NAFLD和NASH的易感性，以及是否可以通过增加线粒体含量或FAOX来预防这一点。目的2)检测低Fit-LCR大鼠是否存在肝脏胰岛素抵抗和肝糖输出异常，这是由于线粒体功能障碍或NAFLD所致。Aim 1和Aim 2都将利用体内饮食高脂肪研究和体外脂质过载研究(原代肝细胞)来检测低有氧适应LCR和高有氧适应Hcr动物对NAFLD和胰岛素抵抗的易感性。此外，将使用体外胰岛素信号转导和体内高胰岛素-正常血糖钳夹方法研究肝脏的胰岛素抵抗。我们还将评估在LCR肝脏或原代肝细胞中腺病毒过表达过氧化物酶体增殖物γ共激活因子1α(PGC-1，刺激线粒体生物发生)或肉碱棕榈酰基转移酶-1(CPT-1，增强现有线粒体中的FAOX)是否可以预防脂质诱导的NAFLD，并改善肝脏对胰岛素的敏感性。这项研究的结果将为有氧健身、肝脏线粒体功能和非酒精性脂肪肝之间的联系提供更好的机制理解。结果还将确定增加肝脏线粒体含量或增加肝脏脂肪酸氧化是否是预防NAFLD或肝脏胰岛素抵抗的有效治疗靶点。

DESCRIPTION (provided by applicant): Non-alcoholic fatty liver disease (NAFLD) can progress to include nonalcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. NAFLD is also implicated in the development of hepatic insulin resistance, a primary player in the development of type 2 diabetes. Recent clinical data demonstrates that patients with low aerobic fitness have increased susceptibility for the development of NAFLD. In addition, evidence from our research group and others has implicated hepatic mitochondrial dysfunction as a primary feature in the development of both NAFLD and hepatic insulin resistance. Our preliminary evidence implicates hepatic mitochondrial dysfunction (low mitochondrial content and reduced fatty acid oxidation (FAOX) as the link between low aerobic fitness and increased susceptibility for both NAFLD and hepatic insulin resistance. However, the links between these factors and the underlying mechanism(s) by which mitochondrial dysfunction leads to NAFLD remain unknown. To unravel these links, we will study two novel strains of rats [high or low capacity runners (HCR/LCR)] with 30% different intrinsic aerobic fitness levels due to two-way divergent selective breeding. The low fit-LCR rat displays reduced mitochondrial content and fatty acid oxidation (FAOX) and NAFLD at a young age and significantly greater hepatic injury compared to the high fit-HCR livers. Thus, the high fit-HCR and low fit-LCR strains provide a novel experimental platform to study the role of aerobic fitness on liver metabolism. The central hypothesis of this proposal is that low aerobic fitness leads to increased risk of NAFLD and hepatic insulin resistance because of mitochondrial dysfunction. The specific aims are the following: Aim 1) to test if the low fit-LCR rats have increased susceptibility to lipid induced NAFLD and NASH, and if this can be prevented by increasing either mitochondrial content or FAOX. Aim 2) to test if the low fit-LCR rats have hepatic insulin resistance and dysregulated hepatic glucose output due to mitochondrial dysfunction or due to NAFLD. Both Aim 1 and Aim 2 will utilize dietary high fat in-vivo studies and lipid overload in-vitro studies (primary hepatocytes) to examine susceptibility for NAFLD and insulin resistance in low aerobically fit LCR and high aerobically fit HCR animals. In addition, hepatic insulin resistance will be studied with in-vitro insulin signaling and in-vivo hyperinsulinemic-euglycemic clamp methods. We will also evaluate if adenoviral overexpression of peroxisome proliferator gamma co-activator 1 alpha (PGC-1, to stimulate mitochondrial biogenesis) or carnitine palmitoyltransferase-1 (CPT-1, to enhance FAOX in existing mitochondria) in LCR livers or primary hepatocytes can protect against lipid induced NAFLD and improve hepatic insulin sensitivity. The outcomes of this study will provide a greater mechanistic understanding of the links between aerobic fitness, hepatic mitochondrial function, and NAFLD. The outcomes will also if determine if increased hepatic mitochondrial content or increased hepatic fatty acid oxidation are effective therapeutic targets to prevent NAFLD or hepatic insulin resistance.